Cheryl Arrowsmith

Cheryl Arrowsmith, Ph.D

Professor, University Health Network, Toronto


Dr. Arrowsmith received her Ph.D. in chemistry from the University of Toronto and carried out postdoctoral research at Stanford University. She is the director of the Toronto Node of the Structural Genomics Consortium (SGC), Senior Scientist at the Princess Margaret Cancer Centre, and Professor of Medical Biophysics at the University of Toronto. Dr. Arrowsmith is an internationally recognized expert in cancer related structural biology & chemical biology and epigenetics. She has been the leader of the Toronto site of the SGC since its inception and coordinates the SGC’s epigenetic chemical probe program. Dr. Arrowsmith was co-founder of Affinium Pharmaceuticals, a structure-based biotech that developed an anti-MRSA antibiotic that recently completed successful phase IIa trials. She has served as a member of 18 scientific advisory boards, grant review panels and journal editorial boards since 2000, including current membership on the Board of Directors of Academic Drug Discovery Consortium (ADDC). Dr. Arrowsmith holds a Canada Research Chair in Structural Genomics at the University of Toronto, has published over 250 peer reviewed articles, with more than 60 of these published in the last 5 years, and is co-author of over 1800 3D protein structures in the Protein DataBank (PDB). Her current research focuses on structural biology and chemical biology approaches to understand how transcriptional and chromatin regulatory proteins recognize, interact with and signal to other molecular components of the cell.

Funded Projects

Brain Tumour Assembloids as Personalized Avatars for Glioblastoma Drug Discovery »

Research Specialties

Research Interests

  • Molecular Pathology

Contact for Collaboration

University Health Network
Pathologists and Researchers who are interested in being part of the OMPRN: